- Sections
- C - Chimie; métallurgie
- C07D - Composés hétérocycliques
- C07D 473/32 - Atome d'azote
Détention brevets de la classe C07D 473/32
Brevets de cette classe: 249
Historique des publications depuis 10 ans
|
15
|
18
|
20
|
19
|
17
|
9
|
28
|
12
|
20
|
1
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Signal Pharmaceuticals, LLC | 188 |
22 |
| Celgene Corporation | 1412 |
8 |
| Boehringer Ingelheim International GmbH | 4629 |
7 |
| Chengdu Baiyu Pharmaceutical Co., Ltd. | 69 |
7 |
| CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 156 |
6 |
| Neupharma, Inc. | 72 |
6 |
| AstraZeneca AB | 3042 |
5 |
| Takeda Pharmaceutical Company Limited | 2961 |
5 |
| Pharmacopeia, Inc. | 34 |
5 |
| S*BIO Pte Ltd. | 28 |
5 |
| The Regents of the University of California | 18943 |
4 |
| Board of Regents, The University of Texas System | 5370 |
4 |
| Incyte Holdings Corporation | 609 |
4 |
| Research Triangle Institute | 389 |
4 |
| Novartis AG | 11238 |
3 |
| F. Hoffmann-La Roche AG | 7958 |
3 |
| Janssen Pharmaceutica N.V. | 3839 |
3 |
| Wyeth LLC | 691 |
3 |
| Purdue Research Foundation | 3277 |
3 |
| Cancer Research Technology Limited | 542 |
3 |
| Autres propriétaires | 139 |